(Q35208663)

7 August 2017

1 reference

title

Targeted therapies for the treatment of cancer (English)

1 reference

7 August 2017

Julian A Kim

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

The American Journal of Surgery

7 August 2017

published in

1 reference

7 August 2017

volume

186

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

264-268

1 reference

Radiation-induced DNA damage and chromatin structure

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Weekly administration of paclitaxel: theoretical and clinical basis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Accomplishments in surgical adjuvant therapy for large bowel cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Humanized antibodies: enhancing therapeutic utility through antibody engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

HER-2/neu as a predictive marker of response to breast cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Cardiac dysfunction in the trastuzumab clinical trials experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Clinical trials of Herceptin(trastuzumab).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Phase I and II clinical trials of trastuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2803%2900212-5

10.1016/S0002-9610(03)00212-5

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference